{"id":"https://openalex.org/W2049345149","doi":"https://doi.org/10.1007/bf00177251","title":"A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infection schedule","display_name":"A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infection schedule","publication_year":1990,"publication_date":"1990-05-01","ids":{"openalex":"https://openalex.org/W2049345149","doi":"https://doi.org/10.1007/bf00177251","mag":"2049345149","pmid":"https://pubmed.ncbi.nlm.nih.gov/2143500"},"language":"en","primary_location":{"id":"doi:10.1007/bf00177251","doi":"https://doi.org/10.1007/bf00177251","is_oa":false,"landing_page_url":"https://doi.org/10.1007/bf00177251","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069843364","display_name":"Carmen Joseph Allegra","orcid":"https://orcid.org/0000-0001-6402-2709","observed_orcids":["https://orcid.org/0000-0001-6402-2709"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Carmen J. Allegra","raw_affiliation_strings":["Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD 20892","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110133366","display_name":"Jean Jenkins","orcid":"https://orcid.org/0000-0002-2354-6810","observed_orcids":["https://orcid.org/0000-0002-2354-6810"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Jenkins","raw_affiliation_strings":["Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110893010","display_name":"Raymond B. Weiss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2800363604","display_name":"Walter Reed National Military Medical Center","ror":"https://ror.org/025cem651","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330347796","https://openalex.org/I2800250139","https://openalex.org/I2800363604","https://openalex.org/I2800386880"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raymond B. Weiss","raw_affiliation_strings":["Section of Medical Oncology, Walter Reed Army Medical Center, 20307, Washington D.C., USA","Section of Medical Oncology, Walter Reed Army Medical Center, Washington D.C., USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Section of Medical Oncology, Walter Reed Army Medical Center, 20307, Washington D.C., USA","institution_ids":["https://openalex.org/I2800363604"]},{"raw_affiliation_string":"Section of Medical Oncology, Walter Reed Army Medical Center, Washington D.C., USA","institution_ids":["https://openalex.org/I2800363604"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024249524","display_name":"Frank M. Balis","orcid":"https://orcid.org/0000-0002-8117-6926","observed_orcids":["https://orcid.org/0000-0002-8117-6926"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frank Balis","raw_affiliation_strings":["Pediatric Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Pediatric Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pediatric Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Pediatric Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110358993","display_name":"James C. Drake","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James C. Drake","raw_affiliation_strings":["Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110093863","display_name":"Jay Brooks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jay Brooks","raw_affiliation_strings":["Navy-NCI Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Navy-NCI Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Navy-NCI Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Navy-NCI Medical Oncology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I4210140884"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077622156","display_name":"Rose V. Thomas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rose Thomas","raw_affiliation_strings":["Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109931105","display_name":"Gregory A. Curt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gregory A. Curt","raw_affiliation_strings":["Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, 20892, Bethesda, MD, USA","institution_ids":["https://openalex.org/I4210140884"]},{"raw_affiliation_string":"Clinical Pharmacology Branch, Division of Cancer Treatment, National Cancer Institute, Bethesda, USA","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210140884"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":4690,"currency":"USD","value_usd":4690},"apc_paid":null,"fwci":0.2851,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.52568633,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"2","first_page":"159","last_page":"166"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6220999956130981,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.6220999956130981,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.12489999830722809,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.03629999980330467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/trimetrexate","display_name":"trimetrexate","score":1.0},{"id":"https://openalex.org/keywords/methotrexate-analogs","display_name":"methotrexate analogs","score":0.7960000038146973},{"id":"https://openalex.org/keywords/dihydrofolate-reductase-inhibitors","display_name":"dihydrofolate reductase inhibitors","score":0.9810000061988831},{"id":"https://openalex.org/keywords/continuous-infusion","display_name":"continuous infusion","score":0.5849999785423279},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8190000057220459},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.824999988079071},{"id":"https://openalex.org/keywords/myelosuppression","display_name":"myelosuppression","score":0.9879999756813049},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8050000071525574},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.7279999852180481},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.8320000171661377},{"id":"https://openalex.org/keywords/nasopharyngeal-carcinoma","display_name":"nasopharyngeal carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-excretion","display_name":"drug excretion","score":0.5149999856948853},{"id":"https://openalex.org/keywords/leukopenia","display_name":"leukopenia","score":0.7049999833106995},{"id":"https://openalex.org/keywords/sepsis","display_name":"sepsis","score":0.902999997138977}],"concepts":[{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.686309278011322},{"id":"https://openalex.org/C68387754","wikidata":"https://www.wikidata.org/wiki/Q7271585","display_name":"Schedule","level":2,"score":0.6083393692970276},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.530720591545105},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3488686680793762},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.21935874223709106},{"id":"https://openalex.org/C111919701","wikidata":"https://www.wikidata.org/wiki/Q9135","display_name":"Operating system","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D016597","descriptor_name":"Trimetrexate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1007/bf00177251","doi":"https://doi.org/10.1007/bf00177251","is_oa":false,"landing_page_url":"https://doi.org/10.1007/bf00177251","pdf_url":null,"source":{"id":"https://openalex.org/S6037287","display_name":"Investigational New Drugs","issn_l":"0167-6997","issn":["0167-6997","1573-0646"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319900","host_organization_name":"Springer Science+Business Media","host_organization_lineage":["https://openalex.org/P4310319900","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Springer Science+Business Media","Springer Nature"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational New Drugs","raw_type":"journal-article"},{"id":"pmid:2143500","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/2143500","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Investigational new drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":14,"referenced_works":["https://openalex.org/W1525999130","https://openalex.org/W1530463449","https://openalex.org/W1605881656","https://openalex.org/W1671197032","https://openalex.org/W1828955744","https://openalex.org/W1967067896","https://openalex.org/W2037156603","https://openalex.org/W2081559073","https://openalex.org/W2106773737","https://openalex.org/W2126870486","https://openalex.org/W2140758506","https://openalex.org/W2163957149","https://openalex.org/W2475350496","https://openalex.org/W2502670554"],"related_works":["https://openalex.org/W2086691599","https://openalex.org/W2041817630","https://openalex.org/W1605881656","https://openalex.org/W2093217501","https://openalex.org/W2106773737","https://openalex.org/W1997065239","https://openalex.org/W2070291488","https://openalex.org/W2036095352","https://openalex.org/W2069507330","https://openalex.org/W1988328608"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}